SANUWAVE TO PROVIDE UPDATE ON RECENTLY ACQUIRED WOUND CARE

SANUWAVE TO PROVIDE UPDATE ON RECENTLY ACQUIRED WOUND CARE

SUWANEE, GA, August 11, 2020 SANUWAVE Health, Inc. (OTCQB:

SNWV) announced today that the

Company will host a conference call on Wednesday, August 12, 2020,

beginning at 1PM Eastern Time to provide an update on the recently

acquired wound care assets.

Shareholders and other interested parties can participate in the

conference call by dialing 844-602-0380 (U.S.) or 862-298-0970

(international) or via webcast at https://www.webcaster4.com/Webcast/Page/2249/36615.

A replay of the conference call will be available through August

19, 2020, by dialing 877-481-4010 (U.S.) or 919-882-2331 and

entering replay passcode 36615 and a replay of the webcast will be

available at https://www.webcaster4.com/Webcast/Page/2249/36615

About SANUWAVE Health, Inc.

SANUWAVE Health, Inc. (OTCQB:SNWV) (www.SANUWAVE.com)

is a shockwave technology company initially focused on the

development and commercialization of patented noninvasive,

biological response activating devices for the repair and

regeneration of skin, musculoskeletal tissue and vascular

structures. SANUWAVE's portfolio of regenerative medicine

products and product candidates activate biologic signaling and

angiogenic responses, producing new vascularization and

microcirculatory improvement, which helps restore the body's

normal healing processes and regeneration. SANUWAVE applies its

technology in wound healing,

orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead

product candidate for the global wound care market,

is US FDA cleared for the treatment of Diabetic Foot Ulcers.

The device is also CE Marked throughout Europe and has device

license approval for the treatment of the skin and subcutaneous

soft tissue in Canada, South Korea, Australia and New Zealand.

SANUWAVE researches, designs, manufactures, markets and services

its products worldwide, and believes it has demonstrated that its

technology is safe and effective in stimulating healing in chronic

conditions of the foot (plantar fasciitis) and the elbow (lateral

epicondylitis) through its U.S. Class III PMA approved

as well as stimulating bone and chronic tendonitis regeneration in

the musculoskeletal environment through the utilization of its

OssaTron, Evotron and

in Europe, Asia and Asia/Pacific. In addition, there are

license/partnership opportunities for SANUWAVE's shockwave

technology for non-medical uses, including energy, water, food and

Forward-Looking Statements

This press release may contain forward-looking

statements within the meaning of the Private Securities

Litigation Reform Act of 1995, such as statements relating to

financial results and plans for future business development

activities, and are thus prospective. Forward-looking statements

include all statements that are not statements of historical fact

regarding intent, belief or current expectations of the Company,

its directors or its officers. Investors are cautioned that any

such forward-looking statements are not guarantees of future

performance and involve risks and uncertainties, many of which are

beyond the Company's ability to control. Actual results may

differ materially from those projected in the forward-looking

statements. Among the key risks, assumptions and factors that may

affect operating results, performance and financial condition are

risks associated with the regulatory approval and marketing of the

Company's product candidates and products, unproven

pre-clinical and clinical development activities, regulatory

oversight, the Company's ability to manage its capital

resource issues, competition, and the other factors discussed in

detail in the Company's periodic filings with the Securities

and Exchange Commission. The Company undertakes no obligation to

update any forward-looking statement.

For additional information about the Company, visit